explore -WSS

explore

author：fashion 2025-10-02 22:56:52 - browse：1

Blue CAR-T cell attacks a leukemia cell. --health coverage from STAT — Engineered receptors on the surface of a T-lymphocyte bind to a leukemia cell. Adobe

The announcement on Tuesday that the Food and Drug Administration was investigating whether CAR-T immunotherapy had itself caused blood cancers initially appeared to be a significant blow to one of the brightest spots in cancer care.

But experts quickly cautioned that risk of this complication is probably minuscule compared to the known risk of secondary cancers from other cancer therapies like chemotherapy and radiation. They noted that CAR-T cells are immune cells that are genetically engineered to fight cancer, and that such genetic modifications were long thought to carry a risk of causing a second, new cancer in patients. The surprise, in a way, is that since CAR-T was first invented more than 10 years ago, that risk had remained just theoretical.

“There’s been a requirement for long-term follow up. I think this is why we’re all surprised. As far as I think any one of us knew, it’d never happened with any of the FDA-approved CAR-Ts,” said Marcela Maus, a cell therapy researcher at Mass General Cancer Center.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： 30 years of 'Listening to Prozac'

entertainment

explore

WSS

UnitedHealth’s Optum accused of antitrust violations in California

Snackable artificial intelligence, expert AI, and the pharma industry

Will the market for weight loss drugs really reach $100 billion?

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

Organ aging and disease risk measured by new blood test

Stem cell treatment guidelines are released by FDA

hotspot

explore

entertainment

Activists slam private health insurers over coverage restrictions

Trump surgeon general acknowledges mistakes during Covid

Medicare proposal to cover medical devices draws a mixed reaction

Listen: Biogen's potential pivot, & Illumina's next chapter

Wildfire smoke exposes gaps in outdoor worker protections

30 years of 'Listening to Prozac'

Walensky prepares to leave CDC — and Congress — behind

30 years of 'Listening to Prozac'

In Memoriam: Notable people who died in 2023

Mayo Clinic plans $5B tech

focus

Organ aging and disease risk measured by new blood test

Organ aging and disease risk measured by new blood test

Snackable artificial intelligence, expert AI, and the pharma industry

Organ aging and disease risk measured by new blood test

Organ aging and disease risk measured by new blood test

With clinical trial data readouts, here's how to spot spin

knowledge

focus

explore

leisure time